The Role of Muscarinic Receptors in the Pathophysiology of Mood Disorders:A Potential Noveltreatment?
Authors:
Open Access
- 26 November 2015
- journal article
- research article
- Published by Bentham Science Publishers Ltd. in Current Neuropharmacology
- Vol. 13 (6) , 739-749
Abstract
The central cholinergic system has been implicated in the pathophysiology of mood disorders. An imbalance in central cholinergic neurotransmitter activity has been proposed to contribute to the manic and depressive episodes typical of these disorders. Neuropharmacological studies into the effects of cholinergic agonists and antagonists on mood state have provided considerable support for this hypothesis. Furthermore, recent clinical studies have shown that the pan-CHRM antagonist, scopolamine, produces rapid-acting antidepressant effects in individuals with either major depressive disorder (MDD) or bipolar disorder (BPD), such as bipolar depression, contrasting the delayed therapeutic response of conventional mood stabilisers and antidepressants. This review presents recent data from neuroimaging, post-mortem and genetic studies supporting the involvement of muscarinic cholinergic receptors (CHRMs), particularly CHRM2, in the pathophysiology of MDD and BPD. Thus, novel drugs that selectively target CHRMs with negligible effects in the peripheral nervous system might produce more rapid and robust clinical improvement in patients with BPD and MDD.Keywords
This publication has 112 references indexed in Scilit:
- Prevalence and Correlates of Bipolar Spectrum Disorder in the World Mental Health Survey InitiativeArchives of General Psychiatry, 2011
- Efficacy of Antimanic Treatments: Meta-analysis of Randomized, Controlled TrialsNeuropsychopharmacology, 2010
- Scopolamine Produces Larger Antidepressant and Antianxiety Effects in Women Than in MenNeuropsychopharmacology, 2010
- Genetic variation in cholinergic muscarinic-2 receptor gene modulates M2 receptor binding in vivo and accounts for reduced binding in bipolar disorderMolecular Psychiatry, 2010
- Replication of Scopolamine's Antidepressant Efficacy in Major Depressive Disorder: A Randomized, Placebo-Controlled Clinical TrialBiological Psychiatry, 2010
- Decreased muscarinic receptor binding in the frontal cortex of bipolar disorder and major depressive disorder subjectsJournal of Affective Disorders, 2009
- Meta-analyses of genetic studies on major depressive disorderMolecular Psychiatry, 2007
- No evidence for association between 19 cholinergic genes and bipolar disorderAmerican Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2007
- Tricyclic antidepressant pharmacology and therapeutic drug interactions updatedBritish Journal of Pharmacology, 2007
- Antidepressant Efficacy of the Antimuscarinic Drug ScopolamineArchives of General Psychiatry, 2006